With many new agents under development, including immuno- and targeted therapies, predictive research models such as Patient Derived Xenografts (PDX) are required for preclinical evaluation. PDX models are proven to be highly predictive models for preclinical drug assessment. The CrownBio bladder cancer PDX collection consists a wide range of models, including subcutaneous and orthotopic models to more closely recapitulate the tumor microenvironment and models carrying FGFR3 and TSC1 mutations. More
Patient-derived xenografts (PDX) offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX collection well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.